Core Insights - Edible Garden AG Incorporated is launching a new product line called JEALOUSY, which focuses on GLP-1 support through a clean-label approach, aimed at enhancing consumer wellness and nutrition [1][3][5] Product Innovations - The JEALOUSY line includes three targeted products: - GLP-1 Jealousy – Fiber for digestive wellness - GLP-1 Jealousy – Hair, Skin & Nails for overall vitality - GLP-1 Jealousy – Protein to support strength and nourishment [3] - The company is also expanding its Kick. Sports Nutrition® platform with new flavor innovations, including an Iced Coffee flavor for protein powders and a White Peach flavor for pre- and post-workout products [4] Market Engagement - Edible Garden is participating in ECRM's Total Wellness session to connect with retail buyers and promote its new product offerings, aiming to establish new commercial partnerships [2][5] Company Overview - Edible Garden is a leader in controlled environment agriculture (CEA), providing sustainable, locally grown organic produce and products through its Zero-Waste Inspired® farming model [6] - The company operates advanced greenhouses and processing facilities across the U.S. and partners with contract growers to ensure product freshness and reduce environmental impact [6][9]

Core Insights - The article discusses the potential of Viking Therapeutics (VKTX) as a contender in the GLP-1 drug market, which is currently dominated by Eli Lilly and Novo Nordisk [1][2][3] Industry Overview - GLP-1 drugs have gained popularity for their effectiveness in weight loss, leading to significant sales for current market leaders [1][5] - There is increasing competition in the GLP-1 market, with other pharmaceutical and biotech companies developing their own candidates [2][6] Company Analysis - Viking Therapeutics is currently studying VK2735, which is in phase 3 trials for an injectable formulation and phase 2 for a pill format, showing promising clinical trial results [6][10] - The dual formulation of VK2735 allows for easy switching between injectable and oral forms, enhancing patient convenience [7] - Viking's stock has historically reacted positively to good news, with a notable 121% increase following positive phase 2 trial data two years ago [9][10] Financial Metrics - Viking Therapeutics has a current market capitalization of $3.2 billion, with a stock price of $28.75 [9] - The stock has a 52-week range of $18.92 to $43.15, indicating volatility and potential for growth [9] Future Outlook - Positive trial results and potential regulatory approval for VK2735 could lead to significant revenue growth and profit for Viking [10] - There are suggestions that Viking could be a takeover target, which may provide additional investment opportunities [10]

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

The stock has climbed in the triple digits over the past three years.Eli Lilly (LLY 1.28%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price explode higher. GLP-1 drugs have been in great demand as they've helped people quickly and safely shed pounds.Now, though, after Lilly stock's 200% increase over three years, you may be wondering if the growth story has fully played out or if there' ...

Key Takeaways NVO shares slid on fears that cheap compounded GLP-1 pills could erode Wegovy demand and pricing power.Regulatory scrutiny intensified as the FDA warned against mass-marketed compounded GLP-1 drugs.NVO stock rebounded after reports that HIMS halted plans for a lower-priced compounded oral semaglutide pill.Danish obesity drugmaker Novo Nordisk (NVO) has had a turbulent few days, with its shares coming under heavy pressure last week. A massive sell-off was sparked by the company’s downbeat 2026 ...

Core Insights - The article discusses the growing consumer interest in telehealth platforms for prescription weight management treatments, particularly through PharmaZee, which connects patients with licensed clinicians for evaluations and prescriptions [5][9][21]. Group 1: Company Overview - PharmaZee operates as a telehealth platform that facilitates access to prescription weight management medications through evaluations by U.S.-licensed physicians [4][21]. - The platform provides compounded semaglutide formulations, which are prepared by licensed pharmacies and are not FDA-approved finished products [22][24]. - PharmaZee emphasizes that it is not a healthcare provider but a technology platform that connects patients with medical professionals [23]. Group 2: Market Context - Novo Nordisk raised concerns about "illegal mass compounding" and "deceptive advertising" in the GLP-1 telehealth market, highlighting issues consumers face when researching compounded GLP-1 access [7][8]. - There is an increasing trend of consumers researching telehealth-based weight management medications, indicating a shift in how individuals approach weight management options [5][9]. Group 3: Consumer Considerations - Consumers evaluating GLP-1 telehealth platforms consider factors such as clinician licensing, prescription approval clarity, and whether the platform provides FDA-approved medications or compounded formulations [16][20]. - Transparency regarding contraindications, ongoing medical supervision, and pharmacy sourcing standards are critical factors for consumers when choosing a telehealth service [18][19]. Group 4: Regulatory and Clinical Insights - GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, require physician evaluation and ongoing medical supervision, with specific contraindications outlined by the FDA [12][27][28]. - The distinction between FDA-approved medications and compounded formulations is crucial for consumers to understand, as compounded medications are not subject to the same regulatory scrutiny [24][25].

Core Insights - Edible Garden AG Incorporated will participate in ECRM's Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session from February 10–12, 2026, in Chicago, Illinois, to showcase its products and engage with retail partners [1][2][3] Company Overview - Edible Garden is a leader in controlled environment agriculture (CEA), providing sustainable, locally grown organic produce through its Zero-Waste Inspired® farming model, available in over 5,000 retail locations across the U.S., Caribbean, and South America [5][7] - The company operates advanced vertically integrated greenhouses and processing facilities, including locations in Grand Rapids, Michigan, Webster City, Iowa, and Belvidere, New Jersey [5] Product Offerings - The company will showcase its Kick Sports Nutrition line, clean labeled sports nutrition, weight management, and GLP-1 support products, along with plant and whey protein powders under the Vitamin Way® and Vitamin Whey® brands at the ECRM event [3][4] - Edible Garden also develops a range of nutrition and specialty food products, including fresh condiments and fermented items [7] Strategic Focus - The participation in the ECRM session aligns with the company's strategy to leverage direct retail engagement for distribution growth, new product introductions, and expanded shelf presence in better-for-you nutrition categories [3][4] - The CEO emphasized the growing consumer interest in GLP-1 support and clean nutrition, indicating a strong market demand for differentiated solutions [4]

Core Insights - The competition in the GLP-1 market has intensified between Eli Lilly and Novo Nordisk following their recent fourth-quarter earnings reports [1] Eli Lilly's Performance - Eli Lilly has gained market leadership with its tirzepatide drugs, Mounjaro and Zepbound, which show superior weight loss efficacy of around 20% compared to semaglutide's 14% [2] - In the fourth quarter, Eli Lilly's revenue increased by 43% to $19.3 billion, surpassing consensus estimates of $17.9 billion, driven by a 46% volume growth despite a 5% decline in realized prices [7] - Mounjaro sales surged 110% to $7.4 billion, exceeding the forecast of $6.7 billion, while Zepbound revenue increased by 123% to $4.3 billion [8] - For 2026, Eli Lilly projects revenue growth of 27% to between $80 billion and $83 billion, above the consensus of $77.6 billion, with adjusted earnings expected to be between $33.50 and $35.00 per share [8] Novo Nordisk's Challenges - Novo Nordisk initially dominated the GLP-1 market but is now facing challenges, including a projected sales decline of 5% to 13% in 2026 at constant exchange rates, marking its first sales drop since 2017 [3][5] - The company reported 10% sales growth for 2025 at constant exchange rates, totaling 309 billion Danish kroner, which fell short of analysts' expectations of 347 billion kroner [4] - The fourth quarter showed an 8% revenue decline, although it slightly beat expectations, while earnings per share missed forecasts [4] - CEO Mike Doustdar cited U.S. pricing discounts, upcoming patent expirations for semaglutide, and competition from Lilly's Zepbound as reasons for the shortfall [5] Market Dynamics - Both companies face common challenges such as pricing pressures, competition, and patent risks, but their trajectories are diverging significantly [9] - Eli Lilly's pipeline, including the anticipated approval of orforglipron in Q2, positions it for sustained strength in the market [10] - Novo Nordisk is attempting to counteract pricing pressures with the launch of an oral version of Wegovy, which has shown early signs of success [6]

VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compa ...

Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita’s potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6- ...